AlloDerm is an acellular dermal matrix derived from donated human skin that undergoes a multi-step proprietary process that removes both the epidermis and the cells that can lead to tissue rejection. AlloDerm has been used in a wide variety of soft tissue grafting procedures such as root coverage, soft tissue augmentation and guided bone regeneration with a consistent record of excellent results. AlloDerm has a safety history of more than a decade. Introduced in 1994 for treating burn patients, AlloDerm has proved its versatility and safety in more than a million diverse procedures in general, orthopedic, urogenital, and dental surgeries. AlloDerm owes its exemplary safety to the safeguards at every step starting from donor screening to the final packaging.
- Tissue accepted only from AATB (American Association of Tissue Banks) compliant tissue banks
- Extensive panel of serology tests
- Proprietary processing technology removes immunogenic cells and minimizes risk of disease transmission
- Final sterility testing ensures that no external pathogens are introduced while processing
The proprietary processing to derive AlloDerm from donor tissue involves a series of steps:
- Treatment with buffered salt solution to separate and eliminate the epidermis
- Series of washes with mild non-denaturing detergent solutions to solubilize and eliminate all cells
- Final freeze drying step using patented technology that prevents damaging ice crystal formation
AlloDerm provides a matrix consisting of collagens, elastin, vascular channels, and proteins that support revascularization, cell repopulation and tissue remodeling. After placement, the patient’s blood infiltrates the AlloDerm graft through retained vascular channels, bringing host cells that adhere to proteins in the matrix. Significant revascularization can begin as early as one week after implantation. The host cells respond to the local environment and the matrix is remodeled into the patient’s own tissue, in a fashion similar to the body’s natural tissue attrition and replacement process. Multiple, randomized clinical trials (RCT) have shown root coverage results with AlloDerm to be equivalent to autogenous connective tissue, and concluded that the procedure was predictable and practical. A meta-analysis of eight RCTs showed no statistically significant differences between the two groups for measured outcomes: recession coverage, keratinized tissue formation, probing depth and clinical attachment levels.
More information on Alloderm can be found online at: http://www.biohorizons.com/alloderm.aspx